Trials / Completed
CompletedNCT05320159
Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
Characteristics, Treatment Patterns, and Treatment Satisfaction Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 17,743 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient characteristics, treatment patterns, and outcomes.
Detailed description
This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient characteristics, treatment patterns, and outcomes. Psoriasis (PsO) patients initiating secukinumab were identified and indexed to the first secukinumab use using the most recent data at study initiation (data period: March 1, 2018 to August 31, 2019) and with a subsequent data refresh (data period: March 1, 2017 - July 31, 2020).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Secukinumab | Included all the patients treated with secukinumab |
Timeline
- Start date
- 2021-02-03
- Primary completion
- 2021-03-31
- Completion
- 2021-03-31
- First posted
- 2022-04-11
- Last updated
- 2022-07-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05320159. Inclusion in this directory is not an endorsement.